8,636 results on '"primary myelofibrosis"'
Search Results
2. Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis
3. A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
4. Managed Access Programs for INC424, Ruxolitinib
5. A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
6. Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (MANIFEST-2)
7. Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER)
8. A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
9. Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE)
10. CD34 Selection Using the Automated CliniMACS Prodigy
11. Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
12. Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
13. Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
14. RVU120 in Patients with Intermediate or High-risk, Primary or Secondary Myelofibrosis (POTAMI-61)
15. High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
16. A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)
17. INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
18. P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
19. A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis
20. A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
21. A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
22. Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
23. A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
24. To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
25. JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
26. CINC424A2X01B Rollover Protocol
27. Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition (HOVON 172 MF)
28. Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)
29. Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
30. A Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis
31. A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis
32. Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis (SENTRY)
33. Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL)
34. To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects
35. A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia (SENTRY-2)
36. An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)
37. Clinical Epidemiology in Contemporary Patients With Myelofibrosis. (ERNEST-3)
38. A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)
39. Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
40. Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
41. A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
42. P1101 in Treating Patients with Myelofibrosis
43. Myeloproliferative Neoplasms (MPNs) Patient Registry
44. Decitabine in Treating Patients With Myelofibrosis
45. Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
46. Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
47. To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
48. To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
49. A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
50. Myeloproliferative Neoplastic Diseases Observatory From Brest (OBENE)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.